Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;22(9):1618-1626.
doi: 10.1111/jch.13960. Epub 2020 Aug 27.

Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial

Affiliations

Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial

Hexuan Zhang et al. J Clin Hypertens (Greenwich). 2020 Sep.

Abstract

Primary aldosteronism (PA) is associated with resistant hypertension and cardiovascular events. There are some limitations of current medical and surgical therapies for PA. To determine the efficacy and safety of catheter-based adrenal artery ablation for treatment of PA patients who refused both surgery and medical therapy, we performed this prospective cohort study. Thirty-six PA patients without apparent aldosteronoma were treated by adrenal artery ablation. Primary outcome was postoperative blood pressure and defined daily dose (DDD) of antihypertensive medications after adrenal ablation. Secondary outcome was biochemical success. We assessed outcomes based on Primary Aldosteronism Surgical Outcome (PASO) criteria. Adrenal CT scan, biochemical evaluation, adrenal artery ablation and adrenal venous sampling (AVS) were underwent. After adrenal ablation, complete clinical success (normotension without antihypertensive medication) was achieved in 9/36 (25.0%) patients and partial clinical success (reduction in blood pressure or less antihypertensive medication) in 13/36 (36.1%) patients. Complete biochemical success (correction of hypokalemia and normalization of aldosterone-to-renin ratio) was achieved in 16/36 (44.4%) patients. Office-based and ambulatory blood pressures were reduced by 17/7 and 11/2 mmHg at 6 months after ablation, respectively. The plasma cortisol level in the ablation group decreased slightly, but no patient developed hypoadrenocorticism. Catheter-based adrenal ablation appears to produce substantial and sustained blood pressure reduction and biochemical improvement, with only minor adverse events in PA patients without apparent aldosteronoma. This therapy could be an important supplement for current PA treatments.

Keywords: adrenal artery ablation; antihypertensive therapy; efficacy and safety; primary aldosteronism.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

FIGURE 1
FIGURE 1
Flowchart of the study. Numbers at each follow‐up are those of patients who had attended each predefined visit at the time. Two patients lost to follow‐up at the visit time. Data from patients who had no less than 3 mo follow‐up were enrolled in the final analysis (n = 36)
FIGURE 2
FIGURE 2
Concordance between CT imaging and AVS laterality. There were 11 patients with normal bilateral adrenals, 13 with unilateral hyperplasia, and 8 with bilateral hyperplasia. In the Figure, data are expressed as n(%). The four APA patients with recurrence PA after surgery were excluded from this analysis. For patients with either no change or bilateral hyperplasia, only AVS can distinguish the ipsilateral or contralateral laterality. APA, aldosterone‐producing adenoma; AVS, adrenal vein sampling; CT, computed tomography

Similar articles

Cited by

References

    1. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889‐1916. - PubMed
    1. Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126‐148. - PubMed
    1. Rossi GP. Primary aldosteronism: JACC State‐of‐the‐Art Review. J Am Coll Cardiol. 2019;74(22):2799‐2811. - PubMed
    1. Mulatero P, Monticone S, Bertello C, et al. Long‐term cardio‐ and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826‐4833. - PubMed
    1. Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta‐analysis. Lancet Diabetes Endocrinol. 2018;6(1):41‐50. - PubMed

Publication types